The Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at US$ 61.6 Bn in 2023 and is expected to exhibit a CAGR of 12. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Human immunoglobulin, also known as intravenous immunoglobulin (IVIG), is a therapeutic preparation of concentrated antibodies extracted from pooled human plasma. It contains mainly immunoglobulin G antibodies and some immunoglobulin A and M. IVIG therapy utilizes the ability of normal donor IgG antibodies to counteract disease processes in a patient. It is used to treat various autoimmune and inflammatory conditions and immune deficiencies. Leading indications include primary immunodeficiencies, immune thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome (GBS), and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
One of the major drivers for the human immunoglobulin (pH4) for intravenous injection market growth is the rising incidence of autoimmune and neurological diseases that require immunoglobulin therapy. For instance, according to the 2019 National Survey Data from the United States, approximately 1 in 125 people suffer from an immunodeficiency and require immunoglobulin replacement therapy, recording an increase of 30% over the past decade. Furthermore, a study published in 2021 stated that globally, neurological disorders are among the leading causes of disability and early death. The increasing prevalence of conditions like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Guillain-Barre syndrome is boosting the demand for immunoglobulin therapy.
Additionally, continual advancements in manufacturing technology for plasma fractionation and development of subcutaneous administration route are also fueling the market growth. Various companies are developing advanced purification techniques to increase product yield and reduce viral inactivation methods to minimize product deterioration. This is increasing the supply of immunoglobulin medicines.
The human immunoglobulin (pH4) for intravenous injection market can be segmented based on the product types into IgG, IgM, IgA, IgE and IgD. Among these, IgG dominates the market with over 90% share. This is because IgG is the most abundant circulating antibody and is important for fighting bacterial and viral infections. It neutralizes toxins and activates the complement system.
Political: Regulations regarding production and processing of human blood products are well established which ensures the safety and efficacy of immunoglobulin products. This promotes growth of the market.
Economic: Increasing healthcare spending worldwide along with growing demand from emerging countries provides opportunities for market growth during the forecast period.
Social: Rising prevalence of immunodeficiency disorders like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and increasing awareness regarding immunoglobulin therapy for various indications is fueling the market growth.
Technological: Advancements in plasma fractionation techniques have enhanced yields of immunoglobulin products. This along with innovations in purity and yield enhance production efficiency.
The Global Human Immunoglobulin (Ph4) For Intravenous Injection Market Growth is expected to witness high, exhibiting 12% CAGR over the forecast period, due to increasing prevalence of immunodeficiency and autoimmune disorders.
The North American region dominates the market owing to established healthcare infrastructure, availability of advanced therapies and rising healthcare expenditure. According to estimates, the North American market is projected to reach a value of US$ 35 Bn by 2030.
Asia Pacific is estimated to be the fastest growing market during the forecast period driven by large patient population, increasing healthcare spending and growing penetration of immunoglobulin therapies in emerging countries like India and China.
Key players operating in the human immunoglobulin (pH4) for intravenous injection market are Takeda Pharmaceutical Company Limited, Baxter, CSL, Bayer AG, Grifols, S.A, Octapharma Brasil Ltda, Shanghai RAAS Blood Products Co Ltd, Hualan Biological Engineering, Inc, Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc), China Resources Boya Bio-pharmaceutical Group Co Ltd, ADMA Biologics, Inc, Sinopharm Group Co. Ltd. These major players are focusing on capacity expansion and new product launches to strengthen their market position.